Limb-girdle muscular dystrophy gene therapy data lift Sarepta

Early data from a Phase I/II study of SRP-9003 to treat a form of limb-girdle muscular dystrophy showed the gene therapy led to functional improvements in all three patients in a low-dose cohort at nine months. Results from a planned higher-dose

Read the full 418 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE